glp 1 roche Ad hoc announcement pursuant to Art. 53 LR] announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity Roche’s New GLP-1 Hits 22%
Pay in 4 interest-free payments of $5.53 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
![glp 1 roche Ad hoc announcement pursuant to Art. 53 LR] announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity Roches New GLP-1 Hits 22%](https://i.ytimg.com/vi/nViBKORbBpA/hq720.jpg?sqp=-oaymwEhCK4FEIIDSFryq4qpAxMIARUAAAAAGAElAADIQj0AgKJD&rs=AOn4CLAoSYndIODidSXCf8NXB9U6qp7Llg)
![glp 1 roche Ad hoc announcement pursuant to Art. 53 LR] announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity Roches New GLP-1 Hits 22%](https://www.insideprecisionmedicine.com/wp-content/uploads/2023/04/IPM_Apr2023_GettyImages_1354824883_ChildHealthCheck-e1681148787738.jpg)
![glp 1 roche Ad hoc announcement pursuant to Art. 53 LR] announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity Roches New GLP-1 Hits 22%](https://image.cnbcfm.com/api/v1/image/108339023-17847889841784788981-47334986735-1080pnbcnews.jpg?v=1784788983&w=750&h=422&vtcrop=y)
![glp 1 roche Ad hoc announcement pursuant to Art. 53 LR] announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity Roches New GLP-1 Hits 22%](https://preview.redd.it/roche-announces-positive-topline-results-from-phase-ii-v0-ex33warfcyfg1.png?width=955&format=png&auto=webp&s=5f77a02e3b4b4e2f12fee581b5b631d47613f779)
![glp 1 roche Ad hoc announcement pursuant to Art. 53 LR] announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity Roches New GLP-1 Hits 22%](https://cphoto.asiae.co.kr/listimglink/1/2026012819584919755_1769597929.png)
























